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ABSTRACT 30 
 Ivacaftor is the first drug to target directly defects in the cystic fibrosis transmembrane 31 
conductance regulator (CFTR), which cause cystic fibrosis (CF).  To understand better how 32 
ivacaftor potentiates CFTR channel gating, here we investigated the effects of temperature on 33 
its action.  As a control, we studied the benzimidazolone UCCF-853, which potentiates CFTR 34 
by a different mechanism.  Using the patch-clamp technique and cells expressing recombinant 35 
CFTR, we studied the single-channel behavior of wild-type and F508del-CFTR, the most 36 
common CF mutation.  Raising the temperature of the intracellular solution from 23 to 37 °C 37 
increased the frequency, but reduced the duration of wild-type and F508del-CFTR channel 38 
openings.  While the open probability (Po) of wild-type CFTR increased progressively as 39 
temperature was elevated, the relationship between Po and temperature for F508del-CFTR 40 
was bell-shaped with a maximum Po at ~30 °C.  For wild-type CFTR and, to a greatly reduced 41 
extent, F508del-CFTR, the temperature-dependence of channel gating was asymmetric with 42 
the opening rate demonstrating greater temperature sensitivity than the closing rate.  At all 43 
temperatures tested, ivacaftor and UCCF-853 potentiated wild-type and F508del-CFTR.  44 
Strikingly, ivacaftor, but not UCCF-853, abolished the asymmetric temperature-dependence of 45 
CFTR channel gating.  At all temperatures tested, Po values of wild-type CFTR in the 46 
presence of ivacaftor were approximately double those of F508del-CFTR, which were 47 
equivalent to or greater than those of wild-type CFTR at 37 °C in the absence of the drug.  We 48 
conclude that the principal effect of ivacaftor is to promote channel opening to abolish the 49 
temperature-dependence of CFTR channel gating. 50 
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INTRODUCTION 55 
 The ATP-binding cassette (ABC) transporter cystic fibrosis transmembrane 56 
conductance regulator (CFTR; ABCC7) (33, 56) is a ligand-gated anion channel that plays a 57 
pivotal role in fluid and electrolyte transport across epithelia (28, 35).  The importance of 58 
CFTR for epithelial physiology is highlighted by its dysfunction in the common, life-59 
shortening genetic disease cystic fibrosis (55).  To date, more than 2,000 mutations have been 60 
identified in the CFTR gene (http://www.genet.sickkids.on.ca/app), although most are very 61 
rare and not all cause disease.  Among those mutations investigated, many disrupt CFTR 62 
expression and function by multiple mechanisms (70).  This is best illustrated by F508del, the 63 
most common CF mutation, a temperature-sensitive folding defect, which not only disrupts 64 
the processing and intracellular transport of CFTR, but also destabilizes the protein at the 65 
plasma membrane and perturbs channel gating (19, 23, 24, 44). 66 
 67 
 To restore function to F508del-CFTR, combination therapy with small molecule 68 
CFTR correctors and potentiators is required (39, 50).  Based on its mechanism of 69 
dysfunction (45), multiple CFTR correctors will likely be required to repair misfolding of 70 
nucleotide-binding domain 1 (NBD1) and restore correct domain assembly (52), leading to 71 
the delivery of F508del-CFTR to the plasma membrane.  Once F508del-CFTR is activated by 72 
phosphorylated with protein kinase A (PKA), CFTR potentiators increase the frequency 73 
and/or duration of channel openings by modifying ATP-dependent or ATP-independent 74 
channel gating (15, 26, 37).  To date, one CFTR potentiator, ivacaftor (VX-770; Vertex 75 
Pharmaceuticals) has been approved for patient use (54, 67).  Ivacaftor treatment of CF 76 
patients with the gating mutation G551D achieves sustained, long-term clinical benefit, 77 
including slower lung function decline and improved nutrition (59).  In combination with the 78 
CFTR corrector lumacaftor, ivacaftor also has clinical benefit for CF patients homozygous for 79 
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the F508del mutation, albeit the health improvements are less than for individuals with 80 
G551D treated with ivacaftor (68, 75).  Nevertheless, laboratory studies suggest that 81 
lumacaftor-ivacaftor combination therapy is likely to be beneficial to CF patients with a 82 
variety of rare missense mutations in CFTR (10, 29, 32). 83 
 84 
 To understand better the action of ivacaftor, here we investigated the temperature-85 
dependence of wild-type and F508del-CFTR potentiation by the small molecule.  Using 86 
excised inside-out membrane patches from cells expressing recombinant CFTR, we studied 87 
single-channel behavior over the temperature range 23 to 37 °C.  As a control, we studied the 88 
benzimidazolone UCCF-853, which potentiates CFTR by a different mechanism to ivacaftor 89 
(2, 13, 39, 51).  Our results demonstrated that ivacaftor, but not UCCF-853, robustly 90 
potentiates CFTR at all temperatures tested, restoring wild-type levels of channel activity (as 91 
measured by open probability (Po)) to F508del-CFTR.  They also revealed that ivacaftor 92 
abolishes the temperature-dependence of CFTR channel gating. 93 
 94 
METHODS 95 
Cells and cell culture 96 
 We used C127 mouse mammary epithelial cells and baby hamster kidney (BHK) cells 97 
stably expressing wild-type human CFTR and the F508del mutation (27, 46).  Cells were 98 
generous gifts of CR O’Riordan (Sanofi Genzyme; C127 cells) and MD Amaral (University 99 
of Lisboa; BHK cells).  Cells were cultured and used as described previously (60, 61) with the 100 
exception that the plasma membrane expression of F508del-CFTR was rescued by either low 101 
temperature incubation (27 °C for 72 – 96 h) or treatment with lumacaftor (3 M for 24 – 48 102 
h at 37 °C).  The single-channel behavior of human CFTR in excised membrane patches from 103 
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different mammalian cell lines is equivalent (wild-type CFTR, (18); F508del-CFTR, Y Wang, 104 
Z Cai and DN Sheppard, unpublished observation). 105 
 106 
Patch-clamp experiments 107 
 CFTR Cl
-
 channels were recorded in excised inside-out membrane patches using 108 
Axopatch 200A and 200B patch-clamp amplifiers and pCLAMP software (all from Molecular 109 
Devices, San Jose, CA, USA) (61).  The pipette (extracellular) solution contained (mM): 140 110 
N-methyl-D-glucamine (NMDG), 140 aspartic acid, 5 CaCl2, 2 MgSO4 and 10 N-111 
tris[Hydroxymethyl]methyl-2-aminoethanesulphonic acid (TES), adjusted to pH 7.3 with Tris 112 
([Cl
-
], 10 mM).  The bath (intracellular) solution contained (mM): 140 NMDG, 3 MgCl2, 1 113 
CsEGTA and 10 TES, adjusted to pH 7.3 with HCl ([Cl
-
], 147 mM; free [Ca
2+
], < 10
-8
 M).  114 
Using a temperature-controlled microscope stage (Brook Industries, Lake Villa, IL, USA), the 115 
temperature of the bath solution was varied between 23 and 37 °C. 116 
 117 
 After excision of inside-out membrane patches, we added the catalytic subunit of 118 
protein kinase A (PKA; 75 nM) and ATP (1 mM) to the intracellular solution within 2 119 
minutes of membrane patch excision to activate CFTR Cl
-
 channels.  To minimize channel 120 
rundown, we added PKA (75 nM), but not protein phosphatase inhibitors, to all intracellular 121 
solutions, maintained millimolar concentrations of ATP (wild-type CFTR, ≥ 0.3 mM; 122 
F508del-CFTR, 1 mM) in the intracellular solution and clamped voltage at –50 mV.  The 123 
effects of temperature on the single-channel behavior of CFTR were tested by increasing the 124 
temperature of the intracellular solution from 23 to 37 °C in 3 – 4 °C increments.  Once 125 
channel activity stabilized at the new test temperature, we acquired 4 – 10 minutes of single-126 
channel data before increasing further the temperature and repeating the acquisition of data.  127 
For wild-type CFTR, there was no difference in channel activity if temperature was decreased 128 
from 37 to 23 °C rather than increased from 23 to 37 °C.  Because of the rundown of F508del-129 
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CFTR at temperatures ≥ 27 °C, we only studied F508del-CFTR by increasing temperature 130 
from 23 to 37 °C. 131 
 132 
 The effects of CFTR potentiators were tested by addition to the intracellular solution 133 
in the continuous presence of ATP (1 mM [F508del-CFTR] or 0.3 mM [wild-type]) and PKA 134 
(75 nM).  We reduced the ATP concentration when testing the effects of potentiators on wild-135 
type CFTR to avoid Po saturation in the presence of potentiators.  For wild-type CFTR, after 136 
acquiring control recordings at temperatures between 23 – 37 °C, test potentiators were added 137 
to the intracellular solution and once channel activity was stable, we acquired data with the 138 
test potentiator over the same temperature range.  For UCCF-853, but not ivacaftor (77), after 139 
washing the potentiator from the recording chamber, control data were acquired again 140 
between 23 – 37 °C.  Because of the rundown of F508del-CFTR Cl- channels in excised 141 
membrane patches at temperatures ≥ 27 °C, data acquired under control conditions used 142 
different excised membranes patches from those used to acquire data in the presence of either 143 
UCCF-853 or ivacaftor. 144 
 145 
 In this study, we used membrane patches containing ≤ 5 active channels (wild-type 146 
CFTR, number of active channels (N) ≤ 5; F508del-CFTR, N ≤ 5).  To determine channel 147 
number, we used the maximum number of simultaneous channel openings observed during an 148 
experiment (16).  To minimize errors, we used experimental conditions that robustly 149 
potentiate channel activity and verified that recordings were of sufficient length to ascertain 150 
the correct number of channels (72).  Despite our precautions, we cannot exclude the 151 
possibility of unobserved F508del-CFTR Cl
-
 channels in excised membrane patches.  152 
Therefore, Po values for F508del-CFTR might possibly be overestimated. 153 
 154 
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 We recorded, filtered and digitized data as described previously (61).  To measure 155 
single-channel current amplitude (i), Gaussian distributions were fit to current amplitude 156 
histograms.  For Po and burst analyses, lists of open- and closed-times were created using a 157 
half-amplitude crossing criterion for event detection and dwell-time histograms constructed as 158 
previously described (61); transitions < 1 ms were excluded from the analysis (eight-pole 159 
Bessel filter rise time (T10-90) ~0.73 ms at fc = 500 Hz).  Histograms were fitted with one or 160 
more component exponential functions using the maximum likelihood method.  For burst 161 
analysis, we used a tc (the time that separates interburst closures from intraburst closures) 162 
determined from closed time histograms (wild-type CFTR: t = 23 °C, tc = 22.5 ± 2.5 ms (n = 163 
6); t = 37 °C, tc = 15.3 ± 0.5 ms (n = 6); low temperature-rescued F508del-CFTR: t = 23 °C, tc 164 
= 30.0 ± 2.3 ms (n = 4); t = 37 °C, tc = 23.2 ± 1.6 ms (n = 4)) (16).  The mean interburst 165 
interval (TIBI) was calculated using Eq. 1 (see Ref. (16)): 166 
   Po = Tb / (TMBD + TIBI),   (Eq. 1) 167 
where Tb = (mean burst duration) x (open probability within a burst).  Mean burst duration 168 
(TMBD) and open probability within a burst (Po(burst)) were determined directly from 169 
experimental data using pCLAMP software.  For wild-type CFTR, only membrane patches 170 
that contained a single active channel were used for burst analyses, whereas for F508del-171 
CFTR, membrane patches contained no more than three active channels.  We analyzed only 172 
bursts of F508del-CFTR single-channel openings with no superimposed openings that were 173 
separated from one another by a time interval > tc. 174 
 175 
 To evaluate the temperature-dependence of current flow and channel gating, we 176 
calculated Q10 temperature coefficients using Eq. 2 (see Ref. (47)): 177 
   Q10 = (k1 / k2) (10 / (t1 – t2))   (Eq. 2) 178 
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where k1 is the current amplitude or rate constant at temperature t1, the higher temperature, 179 
and k2 is the current amplitude or rate constant at temperature t2, the lower temperature; all 180 
values of temperature for these calculations used the Kelvin scale.  For the purpose of 181 
illustration, single-channel records were filtered at 500 Hz and digitized at 5 kHz before file 182 
size compression by 5-fold data reduction. 183 
 184 
Reagents 185 
 The CFTR potentiator UCCF-853 (Cystic Fibrosis Foundation Therapeutics (CFFT) 186 
CFTR Compound Program reference no. P4) (13) was a generous gift of RJ Bridges 187 
(Rosalind Franklin University of Medicine and Science, Chicago, IL, USA) and CFFT 188 
(Bethesda, MD, USA), while ivacaftor and lumacaftor were purchased from Selleck 189 
Chemicals (Stratech Scientific Ltd., Newmarket, UK).  PKA purified from bovine heart was 190 
purchased from Calbiochem (Merck Chemicals Ltd., Nottingham, UK).  All other chemicals 191 
were of reagent grade and supplied by the Sigma-Aldrich Company Ltd. (Gillingham, UK). 192 
 193 
 ATP was dissolved in intracellular solution, while ivacaftor, lumacaftor and UCCF-853 194 
were dissolved in DMSO.  Stock solutions were stored at –20 °C except those of ATP, which 195 
were prepared freshly before each experiment.  Immediately before use, stock solutions were 196 
diluted to final concentrations and, where necessary, the pH of the intracellular solution was 197 
re-adjusted to pH 7.3 to avoid pH-dependent changes in CFTR function (18).  Precautions 198 
against light-sensitive reactions were observed when using CFTR modulators.  DMSO was 199 
without effect on CFTR activity (61).  On completion of experiments, the recording chamber 200 
was thoroughly cleaned before reuse (77). 201 
 202 
Statistics 203 
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 Data recording and analyses were randomized, but not blinded.  Results are expressed 204 
as means ± SEM of n observations, but some group sizes were unequal due to technical 205 
difficulties with the acquisition of single-channel data.  To test for differences between two 206 
groups of data acquired within the same experiment, we used Student’s paired t-test.  To test 207 
for differences between multiple groups of data, we used an analysis of variance (ANOVA) 208 
followed by post-hoc tests.  All tests were performed using SigmaPlot
TM
 (version 13.0; Systat 209 
Software Inc., San Jose, CA, USA).  Differences were considered statistically significant 210 
when P < 0.05.  Data subjected to statistical analysis had n values ≥ 5 per group.  In patch-211 
clamp experiments, n represents the number of individual membrane patches obtained from 212 
different cells.  To avoid pseudo-replication, all experiments were repeated at different times. 213 
 214 
RESULTS 215 
The single-channel activity of wild-type and F508del-CFTR is temperature-dependent 216 
 In this study, we investigated the temperature-dependence of wild-type and F508del-217 
CFTR Cl
-
 channels and the effects of temperature on the action of the CFTR potentiators 218 
ivacaftor (67) and UCCF-853 (P4; (13)).  Using recombinant BHK and C127 cells and the 219 
excised inside-out configuration of the patch-clamp technique, we studied the single-channel 220 
behavior of CFTR between 23 and 37 °C by altering the temperature of the intracellular (bath) 221 
solution.  For F508del-CFTR, all data were acquired while channel activity was stable prior to 222 
channel deactivation (49, 77). 223 
 224 
 Figure 1 shows representative recordings of wild-type and F508del-CFTR Cl
-
 225 
channels following channel activation by PKA (75 nM) made in the presence of ATP (1 mM) 226 
in the intracellular solution, while Figure 2 quantifies the effects of temperature on current 227 
flow through open channels and the pattern of channel gating.  To rescue the plasma 228 
membrane expression of F508del-CFTR, BHK cells expressing F508del-CFTR were either 229 
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incubated at 27 °C for 72 – 96 h or treated with the clinically-approved CFTR corrector 230 
lumacaftor (3 M for 24 – 48 h at 37 °C).  Consistent with previous results (for review, see 231 
Ref. (14)), Figures 1 and 2 demonstrate that the F508del mutation was without effect on 232 
current flow through CFTR Cl
-
 channels in the full-open state, but perturbed channel gating (i, 233 
P = 0.9; Po, P < 0.001; one-way ANOVA with Dunnett’s post-test).  They also show that the 234 
single-channel behavior of F508del-CFTR rescued by low temperature or lumacaftor was 235 
equivalent.  For both wild-type and F508del-CFTR, current flow through the full-open state 236 
increased 0.4-fold from 23 to 37 °C and Q10 temperature coefficient values were comparable 237 
(Fig. 2A and Table 1). 238 
 239 
 The gating behavior of wild-type CFTR is characterized by bursts of channel openings 240 
interrupted by brief, flickery closures separated by longer closures between bursts (Fig. 1A).  241 
Consistent with previous results (5, 47), Figure 1A demonstrates that increasing the 242 
temperature of the intracellular solution had a marked impact on the gating pattern of wild-243 
type CFTR.  As temperature rose from 23 to 37 °C, the frequency of channel openings 244 
increased (as interburst interval [IBI] decreased 6.4-fold), but their duration decreased (as 245 
mean burst duration [MBD] diminished 0.9-fold) with the result that Po was enhanced 1.2-246 
fold (Fig. 2B – D).  At all temperatures tested, F508del-CFTR demonstrated a noticeably 247 
different pattern of channel gating compared to that of wild-type CFTR (Fig. 1).  At 23 °C, 248 
the frequency of F508del-CFTR channel openings was reduced compared to those of wild-249 
type, but their duration was increased, leading to a 2.8-fold lower Po than that of wild-type 250 
CFTR (Fig. 2B – D).  As temperature rose from 23 to 37 °C, the frequency of F508del-CFTR 251 
channel openings increased, but their duration decreased, such that at 37 °C, the MBD of 252 
F508del-CFTR was 0.3-fold shorter than that of wild-type CFTR and its IBI was 6.3-fold 253 
longer with the result that the Po of F508del-CFTR was 10-fold lower than that of wild-type 254 
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CFTR (Fig. 2B – D).  Consistent with previous results (42, 49), the data also show that there 255 
was no difference in the temperature-dependence of channel gating between F508del-CFTR 256 
Cl
-
 channels rescued by low temperature incubation or treatment with lumacaftor (Fig. 2C and 257 
D).  Thus, at both 23 and 37 °C, bursts of F508del-CFTR channel openings were very 258 
infrequent compared to those of wild-type CFTR.  However, at 23 °C openings of F508del-259 
CFTR were greatly prolonged, whereas at 37 °C they were reduced in length compared to 260 
those of wild-type CFTR (Fig. 1). 261 
 262 
 Interestingly, wild-type and F508del-CFTR exhibited strikingly different relationships 263 
between temperature and Po.  For wild-type CFTR, Po values increased progressively between 264 
23 and 37 °C (Fig. 2B).  By contrast, F508del-CFTR rescued by either low temperature or 265 
lumacaftor exhibited a bell-shaped relationship between temperature and Po with values 266 
increasing to a maximum around 30 °C after which they decreased to approach those recorded 267 
at 23 °C (Fig. 2B).  Consistent with previous results (47), wild-type CFTR exhibited 268 
asymmetric Q10 values for channel gating because the opening rate had ~3-fold greater 269 
temperature-dependence than the closing rate (Table 1).  F508del-CFTR rescued by either 270 
low temperature or lumacaftor also had asymmetric Q10 values for channel gating, albeit the 271 
difference in temperature-dependence of opening and closing rates was much less marked and 272 
not statistically significant for VX-809-rescued F508del-CFTR (P = 0.16; Student’s paired t-273 
test) (Table 1). 274 
 275 
Potentiation of wild-type and F508del-CFTR by UCCF-853 is temperature-dependent 276 
 To investigate the effects of temperature on CFTR potentiation by small molecules, 277 
we selected for study ivacaftor (67) and UCCF-853 (P4; (13)).  Figure 3 shows representative 278 
recordings of wild-type and low temperature-rescued F508del-CFTR Cl
-
 channels following 279 
the acute addition of UCCF-853 (10 M) to the intracellular solution bathing excised 280 
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membrane patches acquired at temperatures between 23 and 37 °C, while Figure 4 quantifies 281 
the action of UCCF-853 on current flow and channel gating.  To avoid saturation of the wild-282 
type CFTR response in the presence of UCCF-853, we reduced the ATP concentration in the 283 
intracellular solution to 0.3 mM.  At all temperatures tested, UCCF-853 was without effect on 284 
current flow through wild-type and F508del-CFTR Cl
-
 channels in the full-open state (Figs. 3 285 
and Fig. 4A and Table 1), albeit in these experiments there was a statistically significant 286 
difference in single-channel current amplitude between wild-type and low temperature-287 
rescued F508del-CFTR (P < 0.001; one-way ANOVA with Dunnett’s post-test) (Fig. 4A). 288 
 289 
 Figure 3 demonstrates that for both wild-type and low temperature-rescued F508del-290 
CFTR UCCF-853 (10 M) altered the temperature-dependence of channel gating.  At all 291 
temperatures tested, UCCF-853 enhanced 0.5 – 0.6-fold the Po of wild-type CFTR with the 292 
result that the relationship between Po and temperature was unaltered, but shifted to higher Po 293 
values (Fig. 4B).  Similarly, for low temperature-rescued F508del-CFTR, UCCF-853 elevated 294 
Po values at all temperatures tested, but it also shifted the maximal Po recorded for F508del-295 
CFTR from ~30 °C to ~33 °C with the result that the bell-shaped relationship between 296 
temperature and Po was displaced upwards and to the right.  Burst analysis of wild-type CFTR 297 
channel gating demonstrated that at all temperatures tested, UCCF-853 (10 M) elicited 298 
similar increases in the frequency (by reducing IBI 2.4-fold at 23 
o
C and 0.5-fold at 37 
o
C) 299 
and duration (by increasing MBD 0.3-fold at 23 
o
C and 0.5-fold at 37 
o
C) of channel openings 300 
(Fig. 4C and D).  By contrast, the UCCF-853-dependent enhancement of low temperature-301 
rescued F508del-CFTR channel gating was achieved by increased frequency of channel 302 
openings (23 °C, 1.7-fold; 37 °C, 1.3-fold) (Fig. 4D).  Except at 23 °C where UCCF-853 (10 303 
M) reduced MBD, the small molecule had little or no effect on the duration of F508del-304 
CFTR channel openings (Fig. 4C).  Interestingly, Table 1 reveals that UCCF-853 accentuated 305 
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the asymmetry in Q10 values of channel gating for wild-type and F508del-CFTR by effects on 306 
the temperature-dependence of the opening and closing rates. 307 
 308 
Ivacaftor potentiation of wild-type and F508del-CFTR is temperature-independent 309 
 Next, we examined the temperature-dependence of CFTR potentiation by ivacaftor 310 
(67).  Figure 5 shows representative recordings of wild-type and low temperature-rescued 311 
F508del-CFTR following acute addition of ivacaftor (10 M) to the intracellular solution 312 
acquired at the indicated temperatures and Figure 6 summary data from 4 – 7 experiments.  313 
Like UCCF-853 (Fig. 4A), ivacaftor did not alter current flow through wild-type and F508del-314 
CFTR Cl
-
 channels at each of the temperatures tested between 23 and 37 °C (Figs. 5 and 6A 315 
and Table 1). 316 
 317 
 At all temperatures tested, ivacaftor robustly enhanced the Po of wild-type and low 318 
temperature-rescued F508del-CFTR (Fig. 6B).  Strikingly, the drug eliminated the 319 
temperature-dependence of Po for wild-type and F508del-CFTR Cl
-
 channels with the result 320 
that at all temperatures tested, Po values of acutely potentiated wild-type CFTR were double 321 
those of acutely potentiated low temperature-rescued F508del-CFTR (Fig. 6B).  At 37 °C, the 322 
Po value of low temperature-rescued F508del-CFTR was the same as that of wild-type CFTR 323 
in the absence of the drug, whereas at 23 °C, it was 0.4-fold larger than that of the wild-type 324 
CFTR control (Fig. 6B).  Burst analysis revealed that ivacaftor acutely potentiated wild-type 325 
CFTR by increasing the frequency (by reducing IBI) and duration (by prolonging MBD) of 326 
channel openings (Fig. 6C and D).  The data also reveal that the changes in MBD and IBI of 327 
wild-type CFTR were most marked at 23 °C, where MBD increased 1.9-fold and IBI 328 
decreased 3-fold (Fig. 6C and D).  For low temperature-rescued F508del-CFTR, the major 329 
effect of ivacaftor was on the frequency of channel openings (by reducing IBI 4.7-fold at 23 330 
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°C and 2.1-fold at 37 °C) (Fig. 6D).  However, at all temperatures tested ivacaftor prolonged 331 
channel openings by increasing MBD (Fig. 6C).  Consistent with the drug’s effects on Po, 332 
analysis of Q10 values demonstrates that ivacaftor abolished the asymmetric temperature-333 
dependence of channel gating (Table 1).  For both wild-type and F508del-CFTR, the 334 
temperature-dependence of the opening and closing rates were equivalent in the presence of 335 
ivacaftor (Table 1). 336 
 337 
 To investigate further the action of ivacaftor, we studied the effects of nanomolar 338 
concentrations of ivacaftor and examined the consequences of treating lumacaftor-rescued 339 
F508del-CFTR Cl
-
 channels chronically with the drug.  Because micromolar concentrations of 340 
ivacaftor destabilise F508del-CFTR (20, 48), we repeated our studies of wild-type CFTR 341 
using ivacaftor (100 nM).  Figure 7 shows representative recordings acquired at the indicated 342 
temperatures for low temperature-rescued F508del-CFTR acutely treated with ivacaftor (100 343 
nM) and summary data from 3 – 5 experiments.  Comparison of single-channel records 344 
suggests that reducing the ivacaftor concentration was without effect on current flow through 345 
open channels, but modified channel gating (Figs. 5 – 7).  An analysis of bursts revealed that 346 
there was little or no change in MBD on reducing the ivacaftor concentration from 10 M to 347 
100 nM (Fig. 7D).  By contrast, IBI values were noticeably shorter with ivacaftor (100 nM), 348 
although the temperature-dependence of IBI resembled that observed using ivacaftor (10 M) 349 
(Fig. 7E).  As a result, ivacaftor (100 nM) also abolished the asymmetric temperature-350 
dependence of channel gating (Table 1), while Po values were temperature-independent and 351 
0.5-fold greater than those determined using ivacaftor (10 M) (P = 0.14; one-way ANOVA 352 
with Dunnett’s post-test) (Fig. 7C). 353 
 354 
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 Chronic ivacaftor treatment accentuates the thermoinstability of F508del-CFTR 355 
rescued by lumacaftor (21, 71).  We therefore studied the temperature-dependence of 356 
lumacaftor-rescued F508del-CFTR treated chronically with ivacaftor at 27 and 37 °C only.  357 
Figure 8 shows representative recordings and Figure 9 summary data from 5 – 10 358 
experiments.  Chronic treatment with ivacaftor (1 M) caused a small, albeit statistically 359 
significant (27 
o
C, P < 0.0001; 37 
o
C, P < 0.05) reduction in current flow through fully open 360 
F508del-CFTR Cl
-
 channels at both 27 and 37 °C (Fig. 9A).  By contrast, at both 361 
temperatures, the Po of lumacaftor-rescued F508del-CFTR-treated chronically with ivacaftor 362 
exceeded that of low temperature-rescued F508del-CFTR treated acutely with the drug (Fig. 363 
9B).  As for acute treatment with the drug, the major effect of chronic ivacaftor treatment was 364 
to increase greatly the frequency of F508del-CFTR channel openings, although the drug also 365 
caused some prolongation of channel openings (Fig. 9C and D).  Thus, through effects on the 366 
frequency and duration of channel openings, ivacaftor eliminates the temperature-dependence 367 
of CFTR activity. 368 
 369 
DISCUSSION 370 
 This study investigated the temperature dependence of CFTR potentiation by ivacaftor 371 
and UCCF-853.  At all temperatures tested, ivacaftor and UCCF-853 potentiated CFTR channel 372 
gating.  However, potentiation by ivacaftor, but not UCCF-853, abolished the temperature-373 
dependence of channel gating for both wild-type and F508del-CFTR. 374 
 375 
 The temperature-dependence of current flow through wild-type CFTR resembles that 376 
of different ion channels, whereas the temperature-dependence of CFTR channel gating is 377 
greater than that of many different ion channels, but is similar to that of ATPases (for review, 378 
see Ref. (47)).  Our own analyses of the temperature-dependence of wild-type CFTR concur 379 
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with the findings of Mathews et al. (47) and show that the opening rate of wild-type CFTR is 380 
~3-fold more temperature-dependent than the closing rate.  Of note, Mathews et al. (47) 381 
interpreted the asymmetric temperature-dependence of channel opening and closing as 382 
potential support for a cyclic gating scheme.  Building on these and other data (e.g. (73, 74)), 383 
Csanády et al. (22) used the temperature-dependence of channel gating to propose an 384 
energetic profile for the irreversible gating cycle of CFTR.  The authors’ analysis argues that 385 
channel opening proceeds as a wave of conformational change, which is initiated by 386 
formation of an ATP-bound NBD1:NBD2 dimer and then sweeps to the membrane-spanning 387 
domains (MSDs), leading to opening of the channel pore.  By applying rate-equilibrium free-388 
energy relationship analysis to the hydrolysis-deficient CFTR mutant D1370N, Sorum et al. 389 
(62) verified this model of channel opening and identified the interface between the NBDs 390 
and the MSDs as an energetic barrier to channel opening.  Interestingly, the temperature-391 
dependence of channel closure suggests that large scale protein movements are not required to 392 
close the CFTR pore (22).  Instead, the hydrolysis of a single chemical bond in ATP bound at 393 
ATP-binding site 2 drives pore closure, which precedes partial disassembly of the 394 
NBD1:NBD2 dimer interface (22, 63, 65). 395 
 396 
 Analysis of the temperature-dependence of F508del-CFTR reveals that the mutant 397 
protein exhibits marked thermoinstability in excised membrane patches and planar lipid 398 
bilayers (3, 43, 49, 76).  The irreversible loss of F508del-CFTR channel activity at 37 °C in 399 
the continuous presence of PKA and ATP involves both changes in channel gating and 400 
current flow through open channels (3, 49).  Because revertant (second site) mutations in cis 401 
with F508del prevent the deactivation of F508del-CFTR Cl
-
 channels (4, 43, 76), the 402 
thermoinstability of F508del-CFTR is likely a consequence of structural defects not loss of 403 
anchoring to CFTR-interacting proteins (31).  Previous studies of the temperature dependence 404 
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of F508del-CFTR prior to channel deactivation using the planar lipid bilayer technique show 405 
that F508del-CFTR activity declines with increasing temperature (4, 8).  The present studies 406 
were performed under different experimental conditions using excised membrane patches.  407 
They reveal that prior to channel deactivation, F508del-CFTR has a bell-shaped relationship 408 
between temperature and Po with a maximum Po at ~30 °C, which is modulated by CFTR 409 
potentiators.  As for wild-type CFTR, the temperature-dependence of F508del-CFTR channel 410 
gating was asymmetric, albeit the difference between the opening and closing rates was 411 
greatly reduced and closure of the mutant channel required greater energy than wild-type 412 
CFTR.  This surprising result contrasts with previous work which shows that the F508del 413 
mutation destabilizes the NBD1:NBD2 dimer (38). 414 
 415 
 Strikingly, the present results demonstrate that ivacaftor, but not UCCF-853, eliminated 416 
the temperature-dependence of CFTR channel gating.  In the presence of ivacaftor, Po values 417 
did not alter with increasing temperature and the temperature-dependence of channel gating 418 
was lost.  Because the channel opening rate shows greatest temperature sensitivity (47, 419 
present study), the data suggest that the principal effect of ivacaftor is to promote channel 420 
opening, particularly at temperatures ≤ 30 °C.  Integrating these data with biochemical and 421 
structural data, which demonstrated that ivacaftor reduces thermal stability (12, 49) and 422 
increases conformational flexibility (21), argues that ivacaftor exerts its effects by 423 
destabilizing a closed channel conformation.  In addition, loss of the temperature-dependence 424 
of channel gating suggests that ivacaftor might modify the irreversible cyclic gating scheme 425 
of CFTR to favor a reversible one.  Although this idea is only speculation, analysis of 426 
ivacaftor’s action using the energetic coupling model of CFTR gating (40), demonstrated that 427 
the drug promotes gating transitions that favor channel open states (37) as the present data 428 
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confirm.  Of note, this analysis also provided an explanation for ivacaftor’s ability to promote 429 
both ATP-dependent and ATP-independent channel gating (26, 37). 430 
 431 
 The robust potentiation of CFTR channel gating achieved by ivacaftor confers wild-432 
type levels of channel activity (as measured by Po) on F508del-CFTR and other CF mutants 433 
once delivered to the plasma membrane ((58, 67, 77, 79); present study).  However, it is 434 
important to emphasize that ivacaftor accelerates the deactivation of most, but not all, 435 
F508del-CFTR Cl
-
 channels delivered to the plasma membrane by either low temperature or 436 
lumacaftor (21, 49, 71).  In contrast to ivacaftor, at physiological temperatures, the 437 
benzimidazolone UCCF-853 did not confer wild-type levels of channel activity on low 438 
temperature-rescued F508del-CFTR Cl
-
 channels.  This distinction between ivacaftor and 439 
UCCF-853 might reflect the different potency and efficacy of a clinically-licensed drug and a 440 
screening hit (13, 67).  Alternatively, it might reflect their diverse mechanisms of action.  Al-441 
Nakkash et al. (2) demonstrated that the benzimidazolones NS004 and NS1619 potentiate 442 
CFTR by a mechanism resembling that of genistein (34).  Using the ATP-driven NBD 443 
dimerization model of CFTR channel gating (73, 74), Ai et al. (1) speculated that genistein 444 
might bind at the NBD1:NBD2 dimer interface and accelerate channel opening by lowering 445 
the free energy of the transition state, while slowing channel closure by stabilizing the binding 446 
of ATP at ATP-binding sites 1 and 2.  Consistent with these ideas, Moran et al. (51) used 447 
virtual ligand docking with a molecular model of the NBD1:NBD2 dimer to suggest that 448 
genistein and UCCF-853 bind at the dimer interface. 449 
 450 
 To date, the binding site for ivacaftor has not been identified.  However, several lines 451 
of evidence argue that it is distinct from that of genistein, UCCF-853 and other potentiators 452 
that interact with the NBDs (1, 2, 16).  First, ivacaftor’s ability to potentiate ATP-independent 453 
gating, the drug’s lack of effect on the ATPase activity of CFTR and its potentiation of a 454 
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CFTR construct missing NBD2 (26, 37, 78), argue persuasively that it does not interact with 455 
the ATP-binding sites.  Second, ivacaftor potentiation of R-CFTR, which lacks a large 456 
portion of the R domain (residues 634 – 836; (37)), demonstrates that the drug does not bind 457 
the R domain.  Third, the accumulation of ivacaftor in the inner leaflet of the lipid bilayer and 458 
the reduced sensitivity of some CF mutations in the MSDs to potentiation by ivacaftor (9, 69), 459 
suggests that ivacaftor might exert its effects by interacting with the MSDs.  Such a site of 460 
action supports the drug’s effects on the kinetics of channel gating (37).  Using 461 
hydrogen/deuterium exchange mass spectroscopy, Byrnes et al. (12) investigated ivacaftor 462 
binding to a human CFTR construct with thermostabilizing mutations that themselves modify 463 
CFTR channel gating (4, 57).  Intriguingly, ivacaftor bound to multiple sites on this CFTR 464 
construct, including the Lasso motif (80), transmembrane segment 2 in MSD1, the coupling 465 
helices of intracellular loops 1, 3 and 4 and NBD2 with tightest binding located at the MSD2-466 
NBD1 and MSD2-NBD2 interfaces (12).  These data suggest that ivacaftor might bind near 467 
F508 in a region overlapping the small molecule-binding sites identified by Kalid et al. (41) at 468 
the interface of the NBDs with the MSDs.  Nevertheless, virtual ligand docking data suggest 469 
other potential binding sites for ivacaftor including one at the NBD1:NBD2 interface in the 470 
partially unfolded structure of F508del-CFTR (71). 471 
 472 
 Most studies of CFTR function using the patch-clamp technique are conducted at 473 
room temperature (~23 °C).  An advantage of working at room temperature is that the kinetics 474 
of CFTR channel gating are slowed, permitting the resolution of short-lived gating transitions 475 
that are challenging to detect at 37 °C (e.g. (36)).  However, studying mutant CFTR at room 476 
temperature might preclude full understanding of the mechanism of CFTR dysfunction.  For 477 
example, channel deactivation or rundown, one measure of the plasma membrane instability 478 
of CF mutants, is best observed at temperatures ≥ 30 °C, (3, 43, 49, 76, 77).  Moreover, the 479 
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present results show that at 23 °C, the rate of F508del-CFTR channel closure is markedly 480 
slowed compared to wild-type CFTR, whereas at 37 °C, it is equivalent to that of wild-type 481 
CFTR or even faster, hinting at instability of the open channel conformation, possibly the 482 
interaction of ATP with ATP-binding site 2 (38, 74).  Although we have not evaluated 483 
directly the temperature-dependence of other CF mutants, comparison of our own data with 484 
those of other investigators suggests that temperature influences their gating behavior (e.g. 485 
N1303K-CFTR (25, 32)).  Differences in temperature also likely explain inconsistencies in 486 
the published literature on CFTR modulators.  Previous work showed that the non-487 
hydrolysable ATP analogue AMP-PNP locked CFTR Cl
-
 channels in the open configuration 488 
at temperatures ≤ 30 °C, but at temperatures ≥ 30 °C, locking events were seldom observed, if 489 
at all (17, 47).  Future studies of new CFTR potentiators should include assessment of their 490 
temperature-dependence to assist the identification of small molecules with therapeutic 491 
potential. 492 
 493 
 Although body temperature is normally tightly controlled, fluctuations occur during 494 
fever and chills, symptoms associated with pulmonary exacerbations in CF (30).  Previous 495 
work suggests that body temperature and metabolic activity might influence CFTR behavior 496 
(11).  This idea might explain the different effects of temperature on the single-channel 497 
activity of human CFTR observed in the present study and the CFTR-mediated Cl
-
 498 
conductance of intact microperfused human sweat ducts, which achieved maximal activity 499 
around 30 °C (53).  Alternatively, or in addition, differences in the experimental conditions 500 
used to study recombinant CFTR in excised membrane patches and native CFTR in intact 501 
sweat ducts might provide an explanation.  Because the cellular ATP concentration exceeds 502 
the Km (substrate concentration required for half maximal activity) for CFTR regulation by 503 
ATP and inhibition by ADP is likely to be weak at cellular concentrations (6, 7, 64), the 504 
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balance of protein kinase and phosphatase activity predominantly controls CFTR activity in 505 
vivo (28).  This highlights the therapeutic potential of small molecules that promote the 506 
phosphorylation of CFTR by PKA (e.g. RPL554; (66)).  Importantly, following CFTR 507 
phosphorylation by PKA, ivacaftor potentiates both ATP-dependent and ATP-independent 508 
CFTR channel gating (26, 37), highlighting its value in the treatment of CF (54, 59). 509 
 510 
 In conclusion, wild-type and, to a much reduced extent, F508del-CFTR demonstrate 511 
asymmetric temperature-dependence of channel gating with the opening rate exhibiting 512 
greater temperature sensitivity than the closing rate.  Ivacaftor robustly potentiates CFTR at 513 
all temperatures tested, restoring wild-type levels of channel activity to F508del-CFTR and 514 
abolishing the temperature-dependence of CFTR channel gating.  Thus, temperature has the 515 
potential to influence markedly the gating pattern of CF mutants and the action of small 516 
molecule CFTR modulators. 517 
  518 
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FIGURE LEGENDS 868 
Figure 1: Temperature-dependence of wild-type and F508del-CFTR single-channel 869 
activity  A–C: Representative recordings of wild-type and F508del-CFTR Cl- channels in 870 
excised inside-out membrane patches from recombinant BHK cells.  The plasma membrane 871 
expression of F508del-CFTR was rescued by either low temperature incubation (27 °C for 72 872 
– 96 h) (B) or treatment with lumacaftor (VX-809; 3 M) for 24 – 48 h at 37 °C (C).  The 873 
recordings were acquired at the indicated temperatures in the presence of ATP (1 mM) and 874 
PKA (75 nM) in the intracellular solution.  Dotted lines indicate where channels are closed 875 
and downward deflections correspond to channel openings.  In this and subsequent figures, a 876 
large Cl
-
 concentration gradient was imposed across membrane patches ([Cl
-
]int, 147 mM; [Cl
-
877 
]ext, 10 mM) and membrane voltage was clamped at –50 mV to magnify the size of channel 878 
openings. 879 
 880 
Figure 2: Analysis of the temperature-dependence of wild-type and F508del-CFTR Cl
-
 881 
channels  A–D: Summary data show the change in single-channel current amplitude (i), open 882 
probability (Po), mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 883 
°C for wild-type CFTR and F508del-CFTR rescued by either low temperature incubation (27 884 
°C for 72 – 96 h) or lumacaftor (VX-809; 3 M) for 24 – 48 h at 37 °C).  Data are means ± 885 
SEM (wild-type, A–B, n = 5 – 9, C–D, n = 5 – 6; 27 °C-rescued F508del-CFTR, A–B, n = 5 – 886 
13, C–D, n = 4 – 9; VX-809-rescued F508del-CFTR, A–B, n = 7 – 9, C–D, n = 5 – 8).  In A, 887 
the continuous lines are the fit of first-order regression functions to mean data, whereas in B–888 
D, they are the fit of second-order regression functions to mean data. 889 
 890 
Figure 3: Temperature-dependence of wild-type and F508del-CFTR potentiation by the 891 
small molecule UCCF-853  A–C:  Representative recordings of wild-type and low 892 
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temperature-rescued F508del-CFTR Cl
-
 channels in excised inside-out membrane patches 893 
from recombinant BHK cells acquired at the indicated temperatures to show the effects of 894 
UCCF-853 (P4; 10 M) addition to the intracellular solution.  For wild-type CFTR, ATP (0.3 895 
mM) and PKA (75 nM) were continuously present in the intracellular solution, whereas for 896 
low temperature-rescued F508del-CFTR, ATP (1 mM) and PKA (75 nM) were used.  For low 897 
temperature-rescued F508del-CFTR recordings acquired in the absence of P4, see Figure 1.  898 
Dotted lines indicate where channels are closed and downward deflections correspond to 899 
channel openings. 900 
 901 
Figure 4: Analysis of the temperature-dependence of wild-type and F508del-CFTR 902 
potentiation by UCCF-853  A–D: Summary data show the change in single-channel current 903 
amplitude (i), open probability (Po), mean burst duration (MBD) and interburst interval (IBI) 904 
between 23 and 37 °C for wild-type and low temperature-rescued F508del-CFTR in the 905 
absence and presence of UCCF-853 (P4; 10 M) in the intracellular solution.  Data are means 906 
± SEM (wild-type, A–B, n = 5 – 8, C–D, n = 4 – 5; 27 °C-rescued F508del-CFTR, A–B, n = 4 907 
– 8, C–D, n = 3 – 5).  In A, the continuous lines are the fit of first-order regression functions 908 
to mean data, whereas in B–D, they are the fit of second-order regression functions to mean 909 
data. 910 
 911 
Figure 5: The effects of temperature on wild-type and F508del-CFTR potentiation by 912 
ivacaftor  A and B: Representative recordings of wild-type CFTR and low temperature-913 
rescued F508del-CFTR in excised inside-out membrane patches from recombinant BHK cells 914 
acquired at the indicated temperatures to show the effects of acute addition of ivacaftor (VX-915 
770; 10 M) to the intracellular solution.  For wild-type CFTR, ATP (0.3 mM) and PKA (75 916 
nM) were continuously present in the intracellular solution, whereas for F508del-CFTR, ATP 917 
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(1 mM) and PKA (75 nM) were used.  For control recordings acquired in the absence of 918 
ivacaftor, see Figure 3 for wild-type CFTR and Figure 1 for low temperature-rescued 919 
F508del-CFTR.  Dotted lines indicate where channels are closed and downward deflections 920 
correspond to channel openings. 921 
 922 
Figure 6: Analysis of the temperature-dependence of wild-type and F508del-CFTR 923 
potentiation by ivacaftor  A–D: Summary data show the change in single-channel current 924 
amplitude (i), open probability (Po), mean burst duration (MBD) and interburst interval (IBI) 925 
between 23 and 37 °C for wild-type and low temperature-rescued F508del-CFTR in the 926 
absence and presence of ivacaftor (VX-770; 10 M) added acutely to the intracellular 927 
solution.  Data are means ± SEM (wild-type, A–B, n = 5 – 7, C–D, n = 4 – 6; 27 °C-rescued 928 
F508del-CFTR, n = 4 – 7).  In A, the continuous lines are the fit of first-order regression 929 
functions to mean data, whereas in B–D, they are the fit of second-order regression functions 930 
to mean data. 931 
 932 
Figure 7: The temperature-dependence of F508del-CFTR potentiated by nanomolar 933 
concentrations of ivacaftor  A: Representative recordings of low temperature-rescued 934 
F508del-CFTR in an inside-out membrane patch excised from a recombinant BHK cell 935 
acquired at the indicated temperatures to show the effects of acute addition of ivacaftor (VX-936 
770; 100 nM) to the intracellular solution.  The recordings were made in the continuous 937 
presence of ATP (1 mM) and PKA (75 nM) in the intracellular solution.  For control 938 
recordings acquired in the absence of ivacaftor, see Figure 1.  Dotted lines indicate where 939 
channels are closed and downward deflections correspond to channel openings.  B–E: 940 
Summary data show the change in single-channel current amplitude (i), open probability (Po), 941 
mean burst duration (MBD) and interburst interval (IBI) between 23 and 37 °C for low 942 
40 
 
temperature-rescued F508del-CFTR potentiated by ivacaftor (VX-770; 100 nM).  Data are 943 
means ± SEM (B–C, n = 4 – 5; D–E, n = 3 – 4).  In B and C, the continuous lines are the fit of 944 
first-order regression functions to mean data, whereas in D and E, they are the fit of second-945 
order regression functions to mean data.  For control data acquired in the absence of ivacaftor, 946 
see Figure 6. 947 
 948 
Figure 8: Potentiation of lumacaftor-rescued F508del-CFTR Cl
-
 channels by chronic 949 
treatment with ivacaftor  A and B: Representative recordings of wild-type and F508del-950 
CFTR rescued by either low temperature incubation or treatment with lumacaftor (VX-809; 3 951 
M) in excised inside-out membrane patches from recombinant BHK cells acquired at either 952 
27 °C (A) or 37 °C (B) to show the effects of acute (aVX-770; 10 M) and chronic (cVX-770; 953 
1 M) ivacaftor treatment.  ATP (1 mM) and PKA (75 nM) were continuously present in the 954 
intracellular solution.  Dotted lines indicate where channels are closed and downward 955 
deflections correspond to channel openings. 956 
 957 
Figure 9: Chronic ivacaftor potentiates robustly lumacaftor-rescued F508del-CFTR Cl
-
 958 
channels at 27 and 37 °C  A–D: Summary data show the single-channel current amplitude 959 
(i), open probability (Po), mean burst duration (MBD) and interburst interval (IBI) at 27 and 960 
37 °C for wild-type CFTR and lumacaftor (VX-809)-rescued F508del-CFTR treated either 961 
acutely (aVX-770; 10 M) or chronically (cVX-770; 1 M) with ivacaftor.  Data are means ± 962 
SEM (wild-type: A–B, n = 6 – 10, C–D, n = 6; 27 °C-rescued F508del-CFTR: control, A–B, n 963 
= 10 – 14, C–D, n = 9; aVX-770, A–B, n = 4 – 5, C–D, n = 4; VX-809-rescued F508del-964 
CFTR: control A–B, n = 7 – 8, C–D, n = 5 – 6; aVX-770, A–B, n = 4 – 8, C–D, n = 4 – 6;  965 
cVX-770, A–B, n = 9 – 10, C–D, n = 4 – 5); *, P < 0.05 vs. wild-type CFTR; †, P < 0.05 vs. 966 
F508del-CFTR; ‡, P < 0.05 vs. F508del-CFTR, VX-809. 967 
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TABLES 969 
Table 1: Temperature coefficients of wild-type and F508del-CFTR 970 
 Temperature coefficient (Q10) values 
Conditions i
 
Opening rate 
(1/IBI) 
Closing rate 
(1/MBD) 
WT CFTR  
(1 mM ATP) 
1.39 ± 0.04 4.73 ± 1.14 1.47 ± 0.11* 
WT CFTR  
(0.3 mM ATP) 
1.37 ± 0.05 3.95 ± 0.79 1.50 ± 0.18* 
WT CFTR  
(0.3 mM ATP + P4) 
1.35 ± 0.03 4.46 ± 0.88 1.11 ± 0.09 
WT CFTR  
(0.3 mM ATP + VX-770) 
1.39 ± 0.02 1.89 ± 0.26 1.75 ± 0.12 
F508del-CFTR;  
27 °C-rescued 
1.53 ± 0.03 5.24 3.36 
F508del-CFTR;  
VX-809-rescued 
1.54 ± 0.05 5.38 ± 1.35 3.24 ± 0.33 
F508del-CFTR;  
27 °C-rescued; P4 
1.35 ± 0.04 4.45 1.60 
F508del-CFTR; 27 °C-rescued; 
VX-770 (10 M) 
1.50 ± 0.06 3.45 ± 0.98 3.63 ± 0.62 
F508del-CFTR; 27 °C-rescued; 
VX-770 (100 nM) 
1.30 ± 0.02 3.20 ± 0.45 2.60 ± 0.67 
 971 
Temperature coefficient (Q10) values for single-channel current amplitude (i), channel 972 
opening rate and channel closing rate of wild-type and F508del-CFTR calculated from mean 973 
values of single-channel current amplitude, IBI and MBD for the indicated experimental 974 
conditions; UCCF-853 was tested at 10 M and ivacaftor at 100 nM (F508del-CFTR only) or 975 
10 M.  Data are means ± SEM (n = 4, except wild-type CFTR (0.3 and 1 mM ATP) and VX-976 
809-rescued F508del-CFTR, where n= 5); *, P < 0.05 vs. opening rate.  For low temperature-977 
rescued F508del-CFTR in the absence and presence of UCCF-853, channel deactivation at 37 978 
°C prevented collection of sufficient data to determine Q10 values for opening and closing 979 
rates.  Abbreviations: P4, UCCF-853; VX-770, ivacaftor; VX-809, lumacaftor. 980 









